Literature DB >> 10512068

Thalidomide-induced toxic epidermal necrolysis.

S B Horowitz1, A L Stirling.   

Abstract

Toxic epidermal necrolysis (TEN) is a severe dermatologic disorder associated with mortality of up to 30%. Withdrawal of the causative agent is crucial in its management. Although thalidomide-induced dermatologic disorders rarely were reported before thalidomide was administered to patients positive for the human immunodeficiency virus, hypersensitivity reactions including rash are the agent's major dose-limiting toxicities in this population. As it is prescribed for other immunosuppressed patients, such as those with malignancies, the frequency of dermatologic reactions (including TEN) may increase. A 62-year-old woman developed TEN after approximately 5 weeks of thalidomide therapy for the treatment of a glioblastoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512068     DOI: 10.1592/phco.19.15.1177.30571

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

2.  Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.

Authors:  Pascale Olivier-Abbal; Anne-Charlotte Teisseyre; Jean-Louis Montastruc
Journal:  Med Oncol       Date:  2013-09-28       Impact factor: 3.064

3.  Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.

Authors:  Marianna Colagrande; Mauro Di Ianni; Gino Coletti; Ketty Peris; Maria Concetta Fargnoli; Lorenzo Moretti; Mario Lapecorella; Antonio Tabilio
Journal:  Int J Hematol       Date:  2008-12-04       Impact factor: 2.490

4.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

Review 5.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

6.  Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.

Authors:  Anupam Das; Amrita Sil; Vivek Mishra; Nilay Kanti Das
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

Review 7.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.